Suppr超能文献

精神分裂症患者与正常对照者的认知功能、血浆 MnSOD 活性及 MnSOD Ala-9Val 多态性。

Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.

机构信息

*To whom correspondence should be addressed; Research Building 109, Room 130, 2002 Holcombe Boulevard, Houston, TX 77030, US; tel: 713-791-1414, fax: 713-794-7938, e-mail:

出版信息

Schizophr Bull. 2014 May;40(3):592-601. doi: 10.1093/schbul/sbt045. Epub 2013 Apr 15.

Abstract

Excessive reactive oxygen species are thought to produce oxidative damage that underlies neurodegeneration and cognitive impairment in several disorders including schizophrenia. The functional Ala-9Val polymorphism of the mitochondrial enzyme manganese superoxide dismutase (MnSOD), which detoxifies superoxide radicals to hydrogen peroxide, has been associated with schizophrenia. However, no study has reported its role in cognitive deficits of schizophrenia as mediated through MnSOD activity. We recruited 923 schizophrenic inpatients and 566 healthy controls and compared them on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), plasma MnSOD activity, and the MnSOD Ala-9Val polymorphism. We assessed patient psychopathology using the Positive and Negative Syndrome Scale. We showed that the MnSOD Ala-9Val polymorphism may not contribute directly to the susceptibility to schizophrenia. The Ala variant was associated with worse attention performance among chronic schizophrenic patients but not among normal controls. Plasma MnSOD activity was significantly decreased in patients compared with that in normal controls. Moreover, MnSOD activity among the schizophrenic Ala allele carriers was correlated with the degree of cognitive impairments, especially attention and RBANS total score. We demonstrated an association between the MnSOD Ala-9Val variant and poor attention in schizophrenia. The association between higher MnSOD activity and cognitive impairment in schizophrenia is dependent on the MnSOD Ala-9Val polymorphism.

摘要

过量的活性氧被认为会导致氧化损伤,这是几种疾病(包括精神分裂症)中神经退行性变和认知障碍的基础。线粒体酶锰超氧化物歧化酶(MnSOD)的功能性 Ala-9Val 多态性可以将超氧自由基解毒为过氧化氢,与精神分裂症有关。然而,没有研究报道它在精神分裂症认知缺陷中的作用是通过 MnSOD 活性介导的。我们招募了 923 名精神分裂症住院患者和 566 名健康对照者,并比较了他们在重复神经心理状况评估量表(RBANS)、血浆 MnSOD 活性和 MnSOD Ala-9Val 多态性方面的表现。我们使用阳性和阴性症状量表评估了患者的精神病理学。我们表明,MnSOD Ala-9Val 多态性可能不会直接导致精神分裂症的易感性。Ala 变体与慢性精神分裂症患者的注意力表现较差有关,但与正常对照组无关。与正常对照组相比,患者的血浆 MnSOD 活性显著降低。此外,精神分裂症 Ala 等位基因携带者的 MnSOD 活性与认知障碍的严重程度相关,尤其是注意力和 RBANS 总分。我们证明了 MnSOD Ala-9Val 变体与精神分裂症注意力差之间存在关联。精神分裂症中 MnSOD 活性与认知障碍之间的关联取决于 MnSOD Ala-9Val 多态性。

相似文献

1
Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.
Schizophr Bull. 2014 May;40(3):592-601. doi: 10.1093/schbul/sbt045. Epub 2013 Apr 15.
3
Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with age of smoking initiation in male schizophrenia smokers.
Am J Med Genet B Neuropsychiatr Genet. 2016 Mar;171B(2):243-9. doi: 10.1002/ajmg.b.32398. Epub 2015 Nov 6.
5
Meta-Analyses of Manganese Superoxide Dismutase Activity, Gene Ala-9Val Polymorphism, and the Risk of Schizophrenia.
Medicine (Baltimore). 2015 Sep;94(36):e1507. doi: 10.1097/MD.0000000000001507.
6
Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients.
Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30;34(4):692-6. doi: 10.1016/j.pnpbp.2010.03.026. Epub 2010 Mar 25.
7
Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population.
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):664-72. doi: 10.1016/j.pnpbp.2006.12.019. Epub 2007 Jan 12.
8
10
for Tardive Dyskinesia and Plasma Activity: Association with Ala-9Val Variant: A Randomized, Double-blind Trial.
Curr Neuropharmacol. 2024;22(14):2443-2452. doi: 10.2174/1570159X22666240530095721.

引用本文的文献

2
Association between angiotensin-converting enzyme gene insertion/deletion polymorphism and cognition impairment in patients with schizophrenia.
Psychopharmacology (Berl). 2024 Dec;241(12):2551-2563. doi: 10.1007/s00213-024-06657-y. Epub 2024 Aug 5.
3
Superoxide dismutase and neurological disorders.
IBRO Neurosci Rep. 2024 Jan 23;16:373-394. doi: 10.1016/j.ibneur.2023.11.007. eCollection 2024 Jun.
4
for Tardive Dyskinesia and Plasma Activity: Association with Ala-9Val Variant: A Randomized, Double-blind Trial.
Curr Neuropharmacol. 2024;22(14):2443-2452. doi: 10.2174/1570159X22666240530095721.
7
Low Serum Superoxide Dismutase Is Associated With a High Risk of Cognitive Impairment After Mild Acute Ischemic Stroke.
Front Aging Neurosci. 2022 Feb 28;14:834114. doi: 10.3389/fnagi.2022.834114. eCollection 2022.
8
Antioxidative Defense Genes and Brain Structure in Youth Bipolar Disorder.
Int J Neuropsychopharmacol. 2022 Feb 11;25(2):89-98. doi: 10.1093/ijnp/pyab056.

本文引用的文献

1
Oxidative stress and mitochondrial dysfunction in Down syndrome.
Adv Exp Med Biol. 2012;724:291-9. doi: 10.1007/978-1-4614-0653-2_22.
3
Pharmacological strategies for enhancing cognition in schizophrenia.
Curr Top Behav Neurosci. 2010;4:43-96. doi: 10.1007/7854_2010_39.
4
Oxidative stress in schizophrenia: pathogenetic and therapeutic implications.
Antioxid Redox Signal. 2011 Oct 1;15(7):1999-2002. doi: 10.1089/ars.2010.3646. Epub 2011 May 4.
5
The treatment of cognitive impairment in schizophrenia.
Pharmacol Biochem Behav. 2011 Aug;99(2):245-53. doi: 10.1016/j.pbb.2010.11.009. Epub 2010 Nov 27.
6
7
Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients.
Prog Neuropsychopharmacol Biol Psychiatry. 2010 May 30;34(4):692-6. doi: 10.1016/j.pnpbp.2010.03.026. Epub 2010 Mar 25.
8
Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes.
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):50-6. doi: 10.1016/j.pnpbp.2009.09.020. Epub 2009 Sep 22.
9
Pharmacological cognitive enhancement in schizophrenia.
Neuropsychol Rev. 2009 Sep;19(3):324-35. doi: 10.1007/s11065-009-9103-4. Epub 2009 Jun 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验